CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

Mark Wong*, Rosemary L. Balleine, Michael Collins, Christopher Liddle, Christine L. Clarke, Howard Gurney

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

84 Citations (Scopus)


Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population.

Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients.

Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA).

Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.

Original languageEnglish
Pages (from-to)529-538
Number of pages10
JournalClinical Pharmacology and Therapeutics
Issue number6
Publication statusPublished - Jun 2004
Externally publishedYes


Dive into the research topics of 'CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy'. Together they form a unique fingerprint.

Cite this